Home Companies Catalysts Deep Dives
Tagrisso osimertinib APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Launch2015-11-13
US LOE2032-08-08
Peak Sales Est$9000M
Formulations[{"id":"tagrisso-oral","doses":"40mg, 80mg tablets","route":"Oral","setting":"PATIENT_SELF","frequen
Companies
AZN (ORIGINATOR)100%
Mechanism: EGFR TKI
Expert: Third-generation epidermal growth factor receptor tyrosine kinase inhibitor with selectivity for EGFR T790M resistance mutation while sparing wild-type EGFR.
Everyday: Blocks a protein that tells cancer cells to grow, specifically targeting lung cancers with EGFR mutations.
Targets: ["EGFR"]
Revenue History
PeriodRevenue ($M)
2023$5,799M
2024$6,223M
Q1 2025$1,650M
Q2 2025$1,720M
Q3 2025$1,780M
Programs (2)
IndicationStageKey StudyRegional Status
NSCLC (EGFRm)APPROVEDFLAURA[{"stage":"APPROVED","region":"US","approval_date":"2018-04-18"},{"stage":"APPRO
NSCLC adj (EGFRm)APPROVEDADAURA[{"stage":"APPROVED","region":"US","approval_date":"2018-04-18"},{"stage":"APPRO
Upcoming Catalysts (2)
Tagrisso + Orpathys - EGFRm NSCLC - Ph3 - Topline H1 2026
Datroway ± Tagrisso - EGFRm NSCLC - Ph3 - Topline (TROPION-Lung14) H2 2026
Notes
EGFR TKI (3rd gen). Cornerstone of NSCLC franchise.
Data from Supabase · Updated 2026-03-24